NovoPen Echo® insulin delivery device

NovoPen Echo® insulin delivery device

Blog Article

Jacob Hyllested-Winge,1 Thomas Sparre,2 Line Kynemund Pedersen2 1Novo Nordisk Pharma Ltd, Tokyo, Japan; 2Novo Nordisk A/S, Søborg, Denmark Abstract: The introduction of insulin pen devices has provided easier, well-tolerated, and more convenient treatment regimens for patients with diabetes mellitus.When compared with vial and syringe regimens, insulin pens offer a greater clinical efficacy, improved quality of life, and increased dosing accuracy, particularly at low doses.The portable and Chaste Berry ( Vitex ) discreet nature of pen devices reduces the burden on the patient, facilitates adherence, and subsequently contributes to the improvement in glycemic control.NovoPen Echo® is one of the latest members of the NovoPen® family that has been specifically designed for the pediatric population and is the first to combine half-unit increment (=0.

5 U of insulin) dosing with a simple memory function.The half-unit increment dosing amendments and accurate injection of 0.5 U of insulin are particularly beneficial for children (and insulin-sensitive adults/elders), who often require small insulin doses.The memory function Cooling Racks/Grates can be used to record the time and amount of the last dose, reducing the fear of double dosing or missing a dose.

The memory function also provides parents with extra confidence and security that their child is taking insulin at the correct doses and times.NovoPen Echo is a lightweight, durable insulin delivery pen; it is available in two different colors, which may help to distinguish between different types of insulin, providing more confidence for both users and caregivers.Studies have demonstrated a high level of patient satisfaction, with 80% of users preferring NovoPen Echo to other pediatric insulin pens.Keywords: NovoPen Echo®, memory function, half-unit increment dosing, adherence, children, adolescents .